Visceral leishmaniasis vaccine - IDRI

Drug Profile

Visceral leishmaniasis vaccine - IDRI

Alternative Names: LEISH-F3 + GLA-SE

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bill & Melinda Gates Foundation; Infectious Disease Research Institute
  • Developer Gennova Biopharmaceuticals; Infectious Disease Research Institute; Zydus Cadila
  • Class Leishmaniasis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Visceral leishmaniasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis in India (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis(In volunteers) in USA (IM, Injection)
  • 01 Apr 2014 Infectious Disease Research Institute initiates enrolment in a phase I trial for Visceral leishmaniasis (prevention) in USA (NCT02071758)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top